This comes as seed investments in India during the January-March quarter, which was hit by the lowest level in five quarters

Interview with Anthony S. Fauci, MD, author of Coronavirus Infections—More Than Just the Common Cold

In February 2020 the nature of the 2019-nCoV outbreak is still slowly coming into focus but it appears to be acting more like bad pandemic influenza (efficient spread, overall lower mortality) than like SARS (less efficient spread, overall higher mortality). Anthony Fauci, MD, of the US National Institute of Allergy and Infectious Diseases (NIAID) discusses the latest developments with JAMA Editor in Chief Howard Bauchner.

Coronavirus Resource Center

Physicians in Lombardy, Italy, have been overwhelmed by COVID-19 patients requiring critical care. Based on an existing ECMO center network they developed an ICU network to rapidly identify, triage, and manage patients infected with SARS-2-CoV. Maurizio Cecconi, MD, of Humanitas University in Milan discusses the region’s approach to the surge, including clinical and supply management, health care worker training and protection, and ventilation strategies, with JAMA Editor Howard Bauchner.

Read the article:

Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response

Coronavirus testing will help countries manage coronavirus disease 2019 (COVID-19) but will raise questions about how to counsel patients about their test results. The CDC's Deputy Director for Infectious Diseases Jay C. Butler, MD, talks with JAMA Editor Howard Bauchner about what to advise healthy patients with positive PCR results, sick patients with negative test results, exposed health care workers, and more.

The strategy for managing the COVID-19 pandemic has shifted from containment to mitigation. What does that mean for US hospitals and health systems? Kaiser Permanente Executive Vice President Stephen M. Parodi, MD, discusses telemedicine, protecting health care workers, equipment allocation planning, and more.

The ARDS in COVID-19 patients appears more responsive to PEEP and prone ventilation, but seems to require prolonged ventilation and may be associated with myocardial injury. Michelle N. Gong, MD, MS, Chief of Critical Care Medicine at Montefiore Medical Center in the Bronx, discusses her department's experience managing critically ill coronavirus patients, procuring diagnostic tests and personal protective equipment (PPE) for her staff, and more.

As COVID-19 spreads globally, populations who survive their illness will become immune. Mayo Vaccine Research Group Director Gregory Poland, MD, discusses antibody responses, duration of immunity, vaccine safety, and the prospects for using convalescent serum to passively immunize people unexposed to SARS-CoV-2.

Hospitals need ways to make rational, fair decisions about who gets ICU beds and ventilators if COVID-19 patients overwhelm capacity. Douglas B. White, MD, MAS, Director of the Program on Ethics and Decision Making in Critical Illness at the University of Pittsburgh, discusses a framework for those decisions and a guideline he helped develop for allocation of scarce resources in public health emergencies.

How does the current pandemic compare to historical infectious outbreaks and what can we expect in summer and fall of 2020? Nicholas Christakis, MD, PhD, MPH, director of the Human Nature Lab, Co-director of the Institute of Network Science, and Sterling Professor of Social and Natural Science at Yale University, discusses the epidemiology of COVID-19.

Noninvasive ventilation (NIV), working with dying patients’ families, use of experimental therapies, and more. JAMA Associate Editor Derek Angus, MD, MPH, Distinguished Professor and Chair of Critical Care Medicine at the University of Pittsburgh, provides a COVID-19 ICU management update.

Watch the recording of this livestream

Infectious epidemics have always driven change and triggered discrimination in human societies. Frank Snowden, DPhil, Professor Emeritus of History and History of Medicine at Yale University and author of Epidemics and Society: From the Black Death to the Present (Yale University Press, 2019), puts the COVID-19 pandemic in historical context.

Questions about testing, chloroquine toxicity, duration of immunity and reinfection, and what to expect next are gripping the US as the novel coronavirus spreads. JAMA Associate Editor Preeti Malani, MD, professor of medicine and Chief Health Officer at the University of Michigan, discusses recent developments in a live conversation with JAMA Editor in Chief Howard Bauchner. Recorded on April 6, 2020.

US states are taking the lead in managing the COVID-19 pandemic. What can state governors expect from the federal government and from the US Department of Health and Human Services? Governor Mike Leavitt from Leavitt Partners joins JAMA Editor Howard Bauchner, MD, in this live Q&A. Recorded April 8, 2020.

New York City coronavirus update from Mitchell Katz, MD, President and CEO of NYC Health + Hospitals, the largest municipal public health system in the United States. Recorded April 13, 2020.

JAMA Health Forum editors John Ayanian, MD, MPP, and Melinda Buntin, PhD, discuss changes in US health care and health policy driven by the coronavirus pandemic. Recorded April 16, 2020.

Anne Schuchat, MD, Principal Deputy Director of the Centers for Disease Control and Prevention (CDC), discusses evolution of CDC guidance and latest developments in the COVID-19 pandemic. Recorded Friday May 1, 2020.

With the emergence of coronavirus disease 2019 (COVID-19) as a global pandemic, individuals with preexisting chronic health conditions such as hypertension, diabetes, and cardiovascular disease have been identified as particularly vulnerable. These patients are also more likely than the general population to be taking angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs). As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that causes COVID-19 gains entry into cells via binding to the angiotensin-converting enzyme 2 (ACE2) receptor, concerns have been raised that these therapies might facilitate the transmission of the virus or affect outcomes adversely. Given that ACEI and ARB therapies are known to provide benefit for the underlying conditions treated, stopping ACEI/ARB therapy carries risks. Moreover, local inactivation of the renin-angiotensin-aldosterone system may have protective effects against the development and progression of acute lung failure. In the absence of clinical evidence of benefit or risk of ACEIs/ARBs, current societal statements recommend against discontinuing these drugs other than for standard clinical indications. Robust clinical data are needed to clarify the effect of ACEIs/ARBs on SARS-CoV-2 infection.

From advisories and warnings to smart witticisms, brands across categories are reaching out to consumers over the shadow of Covid-19

India Inc has embraced remote working because of a health scare. But there are important lessons on enabling infrastructure, managing remote teams and ensuring productivity...

The medicinal soap brand is seeing a sharp spurt in demand across the country

Google, Twitter, TikTok, Facebook team up with global health agencies and governments to put up the guardrails on the fake trail

The bank's board of directors has approved a loan to India to strengthen the preparedness of the country's national health system

The podium placard has been the silent messenger of the daily Coronavirus briefings.

Construction activities have resumed, albeit in a staggered manner; in some pockets there is demand for yellow goods as well

Demand for the Eats business grew 89 per cent in April, excluding India, and we've seen an enormous acceleration in demand since mid-March, Khosrowshahi said

As the world population feverishly washes hands, an initiative by a small NGO in Uttar Pradesh seems prescient

Strong social networks got India through the calamity of demonetisation. By not giving migrant workers enough time to get home, the govt has likely deprived them of this

While we don't have a lot of research on the effectiveness of homemade masks in preventing the spread of infection, scientists who study airborne diseases can offer some guidance.

The listing of LIC is being thought when it is still a pre-dominant player in the sector. This is just like in the case of the State Bank of India in 1993

Strengthening primary and community health care, combined with vastly expanded testing, will be key to overcoming the pandemic that threatens to rage through the country